EUGIT Therapeutics

EUGIT Therapeutics

Y Combinator LogoS22ActiveTherapeuticsBiotechOncologyDrug discoveryHealthcare

Engineered T cell based cancer immunotherapy

We are a therapeutics company that is developing immunotherapies for treatment of breast, ovarian and prostate cancers. Starting with gamma delta T cells obtained from healthy donors, our gene engineering approach induces anti-tumor activity that persists within the immunosuppressive tumor microenvironment thereby bringing benefits of immunotherapies to recalcitrant cancers.

Company Launches

EUGIT Therapeutics – Next generation T cell based cancer immunotherapy

Engineered cancer fighting gamma delta T-cells for off-the-shelf treatment of cancers
Read Launch ›
EUGIT Therapeutics
Team Size:1

Active Founders

Nizar Batada

Nizar is the co-founder and CEO at EUGIT, which he started with George Church in 2022. He is an expert in cancer research, genomics and bioinformatics and has published over 25 articles in peer-reviewed journals such as Nature and has obtained nationally competitive grants. Prior to EUGIT, he was a scientist at 23andMe and a tenure track group leader at the University of Edinburgh, UK. Nizar grew up in Toronto and obtained his PhD in Biophysics from Stanford.